USPTO Trademark Application for VISTO Dating App

The USPTO has received an intent-to-use trademark application for the mark "VISTO" by an applicant seeking to offer downloadable mobile applications and online services for dating and matchmaking. The application was filed on March 24, 2026, with an intended use date of March 25, 2026.

USPTO Trademark Application for 'Charge Line' - EV Charging Stations

The USPTO has received an intent-to-use trademark application for the mark 'Charge Line' for electric vehicle charging stations and related goods and services. The application was filed on March 24, 2026, and is designated for use in commerce.

Trademark 99722665 for electric vehicle charging stations

Trademark 99722665 for electric vehicle charging stations

IOPC: BTP Officer Receives Final Written Warning for Excessive Force on Children

The UK's Independent Office for Police Conduct (IOPC) has issued a final written warning to a British Transport Police officer for using excessive force against two children during an arrest. The officer struck both children with his baton shortly after encountering them at London Bridge station.

USPTO Patent Application: IL-17 Antibody Compositions

The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.

Bispecific Molecule Stabilizing Composition Patent Application

The USPTO has published a patent application (US20260083841A1) for a pharmaceutical composition designed to stabilize bispecific antigen-binding molecules at increased concentrations. The composition includes buffer agents, saccharides, and specific stabilizing agents like EDTA or citric acid.

USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells

The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.

USPTO Patent Application: Treating NSCLC with Dostarlimab or Biosimilar

The USPTO has published a patent application detailing a method for treating non-small cell lung cancer (NSCLC) using dostarlimab or a biosimilar. The application outlines a treatment approach for patients previously treated with an immune checkpoint inhibitor.

USPTO Patent Application: Modified Coronavirus Spike Antigen Protein

The USPTO has published a patent application (US20260083836A1) for a modified coronavirus spike antigen protein. The application describes a protein designed to suppress cell membrane fusion ability and improve safety by modifying cleavage sites, aiming to enhance vaccine efficacy and antibody production.

USPTO Patent Application: Phage T4 Nanoparticle Vaccine Platform

The USPTO has published a patent application (US20260083835A1) detailing a modular bacteriophage T4 nanoparticle vaccine platform. This platform is designed for the rapid development of dual COVID-19 and flu mucosal vaccines, administered intranasally without an adjuvant.